Archive for the ‘Gene Therapy Research’ Category

Fallen Angels Biblical Prophecy
Fallen Angels Biblical Prophecy UFO researcher and student of ancient manuscripts, LA Marzulli shared his views on the Nephilim (fallen angels), aliens, biblical prophecy and the Apocalypse. He described a "Luciferian end game" that would take place, possibly after a nuclear attack in the Middle East-- UFOs would appear over cities, and there would be full alien disclosure, crediting the ETs with evolving the human species through genetics. Yet, this will be a demonic deception, he warned, setting people up for the Antichrist. The murders committed by the Nazis during the Holocaust were a kind of "Luciferic sacrifice" that may have opened up portals for fallen angels to enter into our realm, said Marzulli, who noted the rise in UFO sightings directly after WWII. Anomalous creatures such as Mothman may also have arrived through a portal, he conjectured. Marzulli offered analysis of the Fatima incident of 1917 in Portugal. The apparitions seen by some 70000 people were not of Mary of the Bible, but rather a type of deception, he believes. A fourth witness was said to have seen an additional figure-- a child with stringy hair, which he related to the genetic experiments/hybrids associated with alien lore. Tax Protest Update First hour guest Elaine Brown shared an update on the situation surrounding the tax protest she and her husband Ed are involved in. She was joined by Gulf War advocate Joyce Riley, who has befriended the Browns for a number of years. The Browns are ...From:DisclosureBubbleViews:0 0ratingsTime:02:34:23More inScience Technology

Follow this link:
Fallen Angels

Sanford-Burnham speaks with Nobel Laureate Bruce Beutler
Bruce Beutler, MD, professor and director of the Center for the Genetics of Host Defense at UT Southwestern, shared the 2011 Nobel Prize in Physiology or Medicine for his studies of the innate immune system. Working with mice, he discovered toll-like receptors, cellular sensors that recognize bacteria and activate inflammation. Dr. Beutler visited Sanford-Burnham #39;s La Jolla campus to meet with colleagues and deliver a special lecture to a packed auditorium. He also serves on our Scientific Advisory Board. While he was here, we sat down with Dr. Beutler and asked him a few questions about what inspired him to become a scientist, what he #39;s most proud of, where his field is headed in the next decade, and how his life has changed since winning the Nobel Prize.From:SanfordBurnhamViews:3 0ratingsTime:03:35More inScience Technology

View original post here:
Sanford-Burnham speaks with Nobel Laureate Bruce Beutler - Video

Alex Jones Show - David Icke: Human Genetics, The Religion of Death
Tuesday November 6th 2012 Alex talks with author and presenter David Icke about election fraud and human genetics. http://www.davidicke.com Alex Jones Show Complete Playlist: http://www.youtube.com Infowars Nightly News Complete Playlist: http://www.youtube.com Infowars Special Reports Playlist: http://www.youtube.com http://www.infowars.com http://www.prisonplanet.tv http://www.prisonplanet.com httpFrom:AlexJonesCompleteViews:32 4ratingsTime:01:00:04More inNews Politics

Excerpt from:
Alex Jones Show - David Icke: Human Genetics, The Religion of Death - Video

Seattle Genetics, Inc. (SGEN: Quote) Wednesday reported a narrower loss for the third quarter, helped mainly by higher revenues. The company also provided an outlook for the fiscal year 2012, which are currently below analysts' expectations.

Net loss for the quarter improved to $13.7 million or $0.12 per share from $40.7 million or $0.35 per share in the same period last year.

On average, 11 analysts polled by Thomson Reuters expected the company to report a loss of $0.15 per share for the quarter. Anlaysts' estimates typically exclude special items.

Revenues totaled $33.7 million, up from $10.0 million last year. Analysts expected revenues of $52.66 million.

Looking ahead to the fiscal year 2012, the company has forecast revenues in the range of $132 million to $137 million. Analysts expect revenues of $209.03 million.

Seattle Genetics closed Wednesday's trade at $24.47, down 2.12%. Shares dropped 8.05% to $22.50, losing $1.97 in the extended trade on the Nasdaq.

Click here to receive FREE breaking news email alerts for SEATTLE GENETICS INC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

View post:
Seattle Genetics Q3 Loss Narrows, Sees FY12 Outlook Below View - Quick Facts

Human Genetics, The Religion of Death : David Icke
David Icke Human Genetics, The Religion of Death Follow InfoWars Live twitter.com Alex Jones InfoWars !From:InfoWarsLiveViews:2 1ratingsTime:58:00More inNews Politics

Visit link:
Human Genetics, The Religion of Death : David Icke - Video

Public release date: 7-Nov-2012 [ | E-mail | Share ]

Contact: Phyllis Edelman pedelman@genetics-gsa.org 301-634-7302 Genetics Society of America

Bethesda, MDNovember 7, 2012 Listed below are the selected highlights for the November 2012 issue of the Genetics Society of America's journal, GENETICS. The November issue is available online at http://www.genetics.org/content/current. Please credit GENETICS, Vol. 192, November 2012, Copyright 2012.

Please feel free to forward to colleagues who may be interested in these articles.

ISSUE HIGHLIGHTS

An ex vivo model for imprinting: Mutually exclusive binding of Cdx2 and Oct4 as a switch for imprinted and random X-inactivation, pp. 857 Jennifer A. Erwin, Brian del Rosario, Bernhard Payer, and Jeannie T. Lee X chromosome inactivation (XCI) is initially seen only on the parental X chromosome during embryogenesis. This imprinted XCI later becomes random, occurring on either the maternal or paternal X. This article describes a cell culture model for imprinting, discovery of a protein required for imprinted XCI, and the roles of two transcription factors in the switch between imprinted and random XCI in the early mouse embryo.

Small- and large-effect quantitative trait locus interactions underlie variation in yeast sporulation efficiency, pp. 1123 Kim Lorenz and Barak A. Cohen Sporulation efficiency in yeast is a complex trait controlled by alleles of both large and small effect. These investigators report that small-effect alleles differ depending on which large-effect alleles are present in the background, suggesting there are strong interactions between large- and small-effect alleles. Curiously, each large-effect allele had a nearby small effect allele, suggesting that variable alleles for a trait may cluster together in the genome.

Ancient admixture in human history, pp. 1065 Nick Patterson, Priya Moorjani, Yontao Luo, Swapan Mallick, Nadin Rohland, Yiping Zhan, Teri Genschoreck, Teresa Webster, and David Reich This article presents a suite of methods for learning about the history of genetic population mixtures. Application of the methods yielded the striking finding of a clear signal of admixture into northern Europe that likely reflects a history of admixture between Neolithic migrants and the indigenous Mesolithic population of Europe, consistent with recent analyses of ancient bones from Sweden and the genome sequence of the Tyrolean "Iceman".

Elucidating molecular networks that either affect or respond to plasma cortisol concentration in target tissues of liver and muscle, pp. 1109 Siriluck Ponsuksili, Yang Du, Eduard Murani, Manfred Schwerin, and Klaus Wimmers Cortisol has physiological implications for neurobiological, immune, and metabolic processes. This study addresses the genetics of variation in cortisol concentrations by integrating global gene expression and genome-wide association analyses of the level of expression quantitative trait loci detection with causality modeling. The study revealed genes that affect or respond to cortisol levels that are thus of interest in stress biology and animal breeding.

Pathways of genetic adaptation: Multistep origin of mutants under selection without induced mutagenesis in Salmonella enterica, pp. 987 Semarhy Quiones-Soto, Andrew B. Reams, and John R. Roth Bacterial populations plated on growth-limiting medium give rise to well-adapted mutant colonies that accumulate above a lawn of nongrowing cells. This has been attributed to stress-induced mutagenesis of nongrowing cells, but this article presents evidence that this behavior can result from pre-existing small-effect mutations that enable growth and adaptation under selection, with no change in mutation rate.

Go here to see the original:
Genetics Society of America's GENETICS journal highlights for November 2012

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today reported financial results for the third quarter and nine months ended September 30, 2012. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development activities, antibody-drug conjugate (ADC) pipeline and collaborator progress and upcoming milestones.

Through significant commercial, regulatory and clinical development efforts we are continuing to bring ADCETRIS to patients, expanding into other territories under our collaboration with Millennium/Takeda, and advancing the evaluation of ADCETRIS into earlier lines of therapy and other CD30-positive malignancies, said Clay B. Siegall, Ph.D., President and Chief Executive Officer at Seattle Genetics. At the upcoming American Society of Hematology (ASH) annual meeting in December, there will be more than a dozen data presentations by Seattle Genetics and investigators highlighting the evaluation of ADCETRIS in numerous lymphoma types. In addition, at ASH we will introduce our lead preclinical program, SGN-CD33A, which employs our next generation ADC technology, and we expect multiple data presentations by our ADC collaborators. The substantial progress with ADCETRIS and our other pipeline programs, as well as by our collaborators reinforces our ADC leadership position as we strive to change the way cancer is treated.

Recent ADCETRIS Highlights

ADC Collaborator Progress

Other Recent Highlights

Upcoming Milestones

Third Quarter and First Nine Months 2012 Financial Results

Total revenues in the third quarter of 2012 were $49.8 million, compared to $20.7 million in the third quarter of 2011. Total revenues for the nine month period ended September 30, 2012 were $146.9 million, compared to $45.9 million in 2011. Revenues in 2012 include ADCETRIS net product sales of $33.7 million in the third quarter and $102.8 million for the year to date. In addition, revenues include ADCETRIS royalty revenues of $1.7 million in the third quarter and $2.9 million for the year to date related to sales of ADCETRIS by Millennium under its international named patient program. Revenues also reflect amounts earned under the companys ADCETRIS and ADC collaborations totaling $14.5 million in the third quarter of 2012 and $41.1 million for the year to date.

Total costs and expenses for the third quarter of 2012 were $63.6 million, compared to $61.6 million for the third quarter of 2011. For the first nine months of 2012, total costs and expenses were $193.4 million, compared to $171.6 million in the first nine months of 2011. The planned increases in 2012 costs and expenses were primarily driven by ADCETRIS commercialization activities, cost of sales and research and development of the companys other ADC pipeline programs.

Link:
Seattle Genetics Reports Third Quarter 2012 Financial Results

Human Genetics
ll4.me Human Genetics History of Human Genetics.- Human Genome Sequence and Variation.- Chromosomes.- From Genes to Genomics to Proteomics.- Formal Genetics of Humans: Modes of Inheritance.- Linkage Analysis for Monogenic Traits.- Oligogenic Disease.- Formal Genetics of Humans: Multifactorial Inheritance and Common Diseases.- Lessons from the Genome-Wide Studies for Complex Multifactorial Disorders and Traits.- Epigenetics.- Human Gene Mutation: Mechanisms and Consequences.- Human Hemoglobin.- Human Genetics of Infectious Diseases.- Gene Action: Developmental Genetics.- Cancer Genetics.- The Role of the Epigenome in Human Cancers.- Population Genetic Principles and Human Populations.- Consanguinity, Genetic Drift, and Genetic Diseases in Populations with Reduced Numbers of Founders.- Human Evolution.- Comparative Genomics.- Genetics and Genomics of Human Population Structure.- Genetic Epidemiology.- Pharmacogenetics.- Behavioral Genetics.- The Genetics of Personality.- Mental Retardation and Intellectual Disability.- Genetic Factors in Alzheimer Disease and Dementia.- Genetics of Autism.- The Genetics of Alcoholism and Other Addictive Disorders.- Behavioral Aspects of Chromosomal Variants.- Genetics of Schizophrenia and Bipolar Affective Disorder.- Model Organisms for Human Disorders.- Mouse as a Model for Human Disease.- Caenorhabditis elegans, A Simple Worm: Bridging the Gap Between Traditional And Systems-Level Biology.- Drosophila as a Model for Human Disease.- Human ...From:wilmatessier9854Views:0 0ratingsTime:00:16More inPeople Blogs

Original post:
Human Genetics - Video

genetherapy eyes
A BBC item about a new gene therapy for a specific eye sight problemFrom:kees fieggenViews:0 0ratingsTime:02:42More inEducation

See more here:
genetherapy eyes - Video

Treatment proves safe and effective, helps cancer survivors with chronic dry mouth

These initial results clear the way for additional gene therapy studies in the salivary glands. Although sometimes overlooked, salivary glands present an ideal target for gene therapy. They are easily accessible and, once a gene is introduced, it has no obvious escape route into the bloodstream, where it can have unintended consequences.

"You cannot imagine how fulfilling it is to jot down an idea on a napkin in 1991 and then see it enter a clinical trial and help people.," said Bruce Baum, D.M.D., Ph.D., lead author on the study and recently retired NIDCR scientist who spent the last 21 years moving gene therapy in the salivary glands from the research bench to the clinic. "Can a scientist ask for anything better?"

Baum's interest in helping head and neck cancer survivors dates to the early 1980s. While attending to patients in the NIDCR's Dry Mouth Clinic, Baum encountered numerous people with head and neck cancer who had received radiation therapy to shrink their tumors. The radiation, while effective in treating cancer, had inadvertently damaged nearby salivary glands, compromising their ability to secrete saliva into the mouth.

Baum said he was thoroughly frustrated at the time because he had no effective moisture-restoring treatments to offer most patients. They had beaten cancer, but the radiation had left them with a permanent parched sensation in their mouths that diminished their quality of life and often led to chronic oral problems, such as difficulty swallowing, inflammation, infection, bad breath, and pain.

In the early 1990s, as the first gene-therapy studies entered research clinics, Baum saw an opportunity to make a difference. An initial napkin sketch of the procedure and 15 years of research later, Baum and his colleagues had assembled a compelling scientific case in animal studies that the transferred Aquaporin-1 gene, once expressed, will create new water channels in the impermeable salivary gland cells and allow water to flow through them. After rigorous reviews by NIH and the U. S. Food and Drug Administration, the Phase I protocol was launched and the first patients treated in 2008.

The scientists gave 11 head and neck cancer survivors a single-dose injection of the Aquaporin-1 gene directly into one of their two parotid salivary glands, the largest of the major salivary glands. The gene was packaged in a disabled, non-replicating adenovirus, the cause of the common cold when intact but incapable of causing a cold in this case. As is standard in gene therapy studies, the virus served as the vector, or Trojan horse, to deliver the gene into the cells lining the salivary gland.

The scientists found that five participants had increased levels of saliva secretion, as well as a renewed sense of moisture and lubrication in their mouths, within the study's first 42 days, the period covered in this report. Of the six who didn't benefit from gene therapy, none had serious side effects. The most common side effect was a transient and relatively minor immune response against the disabled adenovirus.

"It is time to evaluate a different vector to deliver the Aquaporin-1 gene, one that will cause only a minimal immune response," said Baum. "But these data will serve as stepping stones for other scientists to improve on this first attempt in the years ahead. The future for applications of gene therapy in the salivary gland is bright."

Originally posted here:
Gene Therapy Can be Performed Safely in the Human Salivary Gland

SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today reported that uniQure's Glybera (alipogene tiparvovec) approval by the European Commission, the first gene therapy approval by a major health regulatory authority, represents a significant milestone and validation for the gene therapy industry. Glybera is a treatment for patients diagnosed with an inherited metabolic disease called familial lipoprotein lipase deficiency (LPLD or familial hyperchylomicronemia), who suffer from severe or multiple pancreatitis attacks despite dietary fat restrictions. The European Commission's marketing authorization of Glybera covers all 27 European member states and uniQure plans to apply for regulatory approval in the U.S., Canada and other countries.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

"The EU approval of Glybera represents a major milestone for the global gene therapy industry," stated Christopher J. Reinhard, Chairman and CEO of Cardium. "This is an important step forward for our field and the millions of patients expected to benefit from new and innovative gene-based therapeutics. Gene therapy offers the opportunity to simplify treatments for serious medical problems and to develop new products for which there are no current medical treatments."

Cardium's late-stage gene therapy Generx product candidate (Ad5FGF-4) is a disease-modifying interventional cardiology biologic being developed as a one-time non-surgical treatment for patients with coronary artery disease. Generx can be delivered using a standard cardiac catheter and is capable of promoting and enhancing cardiac perfusion in the heart through the enlargement of pre-existing collateral arterioles (arteriogenesis) and the formation of new capillary vessels (angiogenesis).

About Cardium

Cardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's newly-acquired To Go Brands nutraceutical business. The Company's lead commercial product, Excellagen topical gel for wound care management, has received FDA clearance for marketing and sale in the United States. Cardium's lead clinical development product candidate Generx is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. To Go Brands develops, markets and sells dietary supplements through established regional and national retailers. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. News from Cardium is located at http://www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there can be no assurance that the approval of a gene therapy in Europe will improve the prospects for other gene therapy products; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized and their use reimbursed, or will enhance our market value; that our To Go Brands business can be successfully integrated and expanded; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2012 Cardium Therapeutics, Inc. All rights reserved. For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com.

Cardium Therapeutics, Generx, Cardionovo, Tissue Repair, Gene Activated Matrix, GAM, Excellagen, Excellarate, Osteorate, MedPodium, Appexium, Line, Alena, Cerex, D-Sorb, Neo-Energy, Neo-Carb Bloc, Neo-Chill, and Nutra-Appsare trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company. To Go Brands is a trademark of To Go Brands, Inc.

Excerpt from:
European Union's First Gene Therapy Approval Represents Major Advancement For Industry

cord blood center | Cord Blood Transplantation - A Life Savior Technique
http://www.cordbloodrecommendation.com Storing your babies blood is painless, and causes no harm or pain to the child or mother. Anything that can help cure illnesses and several genetic diseases is worth at least researching and contemplating because you really do never know when you may need it. This type of stem cells is found in baby cord blood and adult bone marrow. Umbilical blood banking provides the ideal stem cell match should a patient require stem cell therapy in their lifetime. Hence opt for cord blood storage banks that can show proof of successful transplants from the cord blood units they have stored in order to avoid rude shocks. If you are an expecting mother, you can look for a bank or designated donation hospital in your community. In cases of leukemia, stem cells can be used to generate healthy blood and fight off the cancer cells in the body. Furthermore, collecting umbilical cord blood has no controversy since the process does not cause the destruction on the embryos and fetus. ""Leukemia is a type of cancer that begins from those tissues in the body that form blood. Ultra-modern cord blood banking technologies induce multiplication of cord blood stem cells by ex vivo expansion. Last but not the least, if you do not want to store the blood for your personal usage in any of these banks you can also donate it to the Medical Institutes for research purposes. Stem cells, researchers discovered, could cure many diseases such as leukemia and help others such as ...From:Implantes DentalesViews:1 0ratingsTime:01:31More inTravel Events

Original post:
cord blood center | Cord Blood Transplantation - A Life Savior Technique - Video

stem cells | Cryo-Cell - Cord Blood Banking Information For Parents
http://www.cordbloodrecommendation.com You never know when you might need this blood and it might give your child a new life. Why Bank Cord Blood?Cell therapy has become a more ideal method to treat certain diseases than bone morrow transplants. Most of the private and public banks were founded during the 1990s. In a laboratory test, cord blood stem cells were transplanted into rodents with controlled strokes. With the success from transfusions creating immune system stability, and creating new oxygen baring cells for many diseases, researchers are hoping that more diseases can not only be treated effectively, but possibly stopped in their tracks altogether. In cancer patients, such as those with leukemia, the introduction of HSC #39;s into the body may rapidly produce healthy cells that can replace destroyed cells from chemotherapy and/or hopefully prevent infections that often create complications or even death, during the treatment process. If you pass all the tests you will be free to donate your baby #39;s blood. Although some will allow you to prepay during your pregnancy so as to not have to pay the amount all in one lump sum, but in general all initial fees must be paid well in advance of delivery in order to utilize the private storage services. According to the most current data, the prospect of needing a stem cell transplant in any individuals Life is 1 in 217! So you can imagine that the likelihood of your baby, or one of your family members needing this kind of help is ...From:kristinagraddyViews:1 0ratingsTime:01:31More inTravel Events

Read the rest here:
stem cells | Cryo-Cell - Cord Blood Banking Information For Parents - Video

blood banks | Cryo-Cell - Cord Blood Banking Information For Parents
http://www.cordbloodrecommendation.com One main reason behind the importance of saving your newborn #39;s blood is that its use is mostly geared to close relatives within your direct bloodline. Why Bank Cord Blood?Cell therapy has become a more ideal method to treat certain diseases than bone morrow transplants. Human umbilical cord blood cells are rich in mescenchymal progenitor cells and contain a large number of endothelial cell precursors. I know this all sounds very technical and expensive. Relatives or other close friends who haven #39;t gone through cord blood banking may also benefit from the stem cells that can be derived from cord blood banking if and only if they will pose a close match with the cord blood banking donor #39;s stem cells. How is it stored?At the time of the baby #39;s birth, the doctor or nurse takes the cord blood and cryogenically freezes it. 4. As for other applications, though promising, they are still in the research stage. Stem cells are early cells that are capable of developing into red and white blood cells, and platelets. Numerous study reports reveal that more than 50 per cent of the potential donors are not eligible to donate cord blood. There is no clear proof to validate that stem cells of a relative are more successful than those taken from a stranger. So, day-by-day man is trying to reach the ultimate knowledge. Even if a lot of people think that extracting stem cells from human embryos is unethical, those stem cells can also be extracted from ...From:LosHotelesEnBogotaViews:2 0ratingsTime:01:31More inTravel Events

Here is the original post:
blood banks | Cryo-Cell - Cord Blood Banking Information For Parents - Video

FAQ-10 of 19: Can Stem Cells Cause Cancer From Stem Cell Therapy?
youtu.be People ask us if stem cell therapy can CAUSE cancer, and they are wise to be wary, but stem cell therapy has been proving effective AGAINST cancer, and has not cause any known cases of cancer to-date. For more personalized information, visit StemCell-Asia.info now.From:Karridine1Views:1 0ratingsTime:01:06More inPeople Blogs

Link:
FAQ-10 of 19: Can Stem Cells Cause Cancer From Stem Cell Therapy? - Video

FAQ-11 of 19: For Stem Cell Therapy, Why Thailand #39;s Licensed Stem Cell Treatments?
youtu.be You may wonder why coming to Thailand is a better investment of time, energy and resources, so here are some answers. For more personalized information as to how your condition might respond to stem cell therapy, go to the Apply Now page and send in copies of your medical records with an Application for Consideration. StemCell-Asia.infoFrom:Karridine1Views:1 0ratingsTime:01:16More inPeople Blogs

Visit link:
FAQ-11 of 19: For Stem Cell Therapy, Why Thailand's Licensed Stem Cell Treatments? - Video

FAQ-14 of 19: Do We Provide a Guarantee for Stem Cell Therapy?
youtu.be This video addresses the ethical, practical aspects of a #39;guarantee #39; for stem cell therapy or stem cell treatments. For more detailed information concerning guarantees, stem cell therapy and your particular problem, visit bit.ly today.From:Karridine1Views:0 0ratingsTime:01:15More inPeople Blogs

Read more:
FAQ-14 of 19: Do We Provide a Guarantee for Stem Cell Therapy? - Video

Arthritis
Call: 305-695-7777 For More Information Arthritis has been something historically very hard to cure, but we maybe one step closer to a cure by using stem cell therapies instead of steroids and other types of medications. At Miami Beach Foot and Ankle Surgery we have been utilizing PRP (platelet rich plasma) therapy as well as amniotic stem cell therapy, which is important in the world of arthritis.From:MiamiFootSurgeryViews:11 0ratingsTime:01:12More inHowto Style

Original post:
Arthritis - Video

Muscular Dystrophy Before and After Stem Cell Therapy
He took stem cell therapy at NeuroGen. Previously when he was climbing stairs, he was widening steps and climbing stairs. And he was taking more time, now he is taking less time. Climb stairs straight. Previously during sit to stand, he was taking support of hands and was coming up, but now he is not taking support. Previously when he was sitting on floor, he was facing in coming up and facing problem in walking few steps. But after stem cell therapy he can walk normally now. Now changes are seen. Stem Cell Treatment done at Neurogen ,Brain Spine Institute, Surana Sethia Hospital and Research Centre, Suman Nagar, Sion-Trombay Road, Chembur,Mumbai-71. Website -- http://www.neurogen.in http://www.stemcellsmumbai.com Tel: - +91 9920 200400, 022-25283706From:neurogenbsiViews:0 0ratingsTime:00:37More inScience Technology

The rest is here:
Muscular Dystrophy Before and After Stem Cell Therapy - Video

Stem Cell Malaysia | Stem Cell Therapy
stemcellmalaysia.com Stem Cell Malaysia shares with you actual user experience on stem cell therapy. Stem Cell Malaysia also provides useful information on stem cells, stem cell therapy, stem cell research and stem cell newsFrom:stemcells2012Views:102 4ratingsTime:03:17More inHowto Style

Excerpt from:
Stem Cell Malaysia | Stem Cell Therapy - Video

The Patients of Angeles Health International
What our patients have to say about their experiences at Angeles Health International. All patients were treated for different conditions, in separate departments throughout our facilities. Angeles Health International offer cutting edge care, procedures and treatment in the following areas: Weight Loss Surgery - http://www.weightlossmex.com Stem Cell Therapy - http://www.stemcellmx.com Multiple Sclerosis Treatment - http://www.ccsvi.mx Effective Chemotherapy-free Cancer Treatment - http://www.cancertreatmentmx.com Visit the Angeles Health International website here: http://www.angeleshealth.com There are a team of healthcare professionals waiting to hear from you. Contact Angeles Health International toll free on: 1.866.668.9263From:AngelesHealthViews:0 0ratingsTime:03:06More inScience Technology

The rest is here:
The Patients of Angeles Health International - Video

Stem Cells Doctor in Mexico Shares his Expertise
http://www.mexicohealth.com The video shows a stem cells doctor in Mexico discussing various procedures he specializes in, which notably are multiple sclerosis, brain degenerative disorders, and eye sight rectification. This stem cell specialist has treated over forty patients using cutting edge stem cell therapies. Despite cynical attitudes from different quarters, this doctor represents the vanguard for stem cell treatments for progressively degenerative conditions. To read the transcript and to get a free quote from stem cells doctor in Mexico. Click the link above. Related Searches: Stem Cell Therapy Doctors Mexico, stem cell treatment glaucoma mexico, stem cell therapy brain disorders mexico, stem cell therapy brain injury mexico, stem cell treatment spinal cord MX,From:mexicohealthViews:3 0ratingsTime:04:05More inPeople Blogs

View post:
Stem Cells Doctor in Mexico Shares his Expertise - Video

Stem Cells Treatment in Mexico - Reports You #39;ll Need
http://www.mexicohealth.com The video shows a top stem cell specialist emphasizing the importance of reports and records in devising a sure shot stem cell treatment. Mexico is going where others have feared to tread by investing heavily in stem cell research and development. Not all conditions are curable using stem cells. Some even require a certain degree of faith in your doctor. This doctor has helped more than 40 patients to get up on their feet. Communication is the key, as this doctor points out. If you #39;re mulling over getting a stem cell treatment in Mexico, for yourself or somebody you know, always remember to carry exhaustive reports. To get a free quote, click the link above. Related Searches: stem cell therapy specialists mexico, Stem Cell Treatment for Multiple Sclerosis Mexico, Stem Cell Therapy in Mexico for Chronic Heart Failure, Adult Stem Cell Treatment in Mexico, Stem Cell Therapy for Diabetes Mexico, stem cell treatment for brain damage Mexico, Stem Cell Treatment for Neurodegenerative Conditions mexico, Stem Cell Treatment for Eye Diseases Mexico, Stem Cell Treatment for Heart Conditions Mexico, Stem Cell Therapy for Brain Injury Mexico,From:mexicohealthViews:3 0ratingsTime:02:08More inPeople Blogs

See the rest here:
Stem Cells Treatment in Mexico - Reports You'll Need - Video

Autologous and Adult Stem Cells Transplant in Mexico
http://www.mexicohealth.com The video shows a top stem cell specialist in Mexico explaining why autologous stem cell treatment is a better choice than adult stem cell transplant. The doctor goes on to caution about risks of reaction in case of adult stem cells transplant. In some cases, the reaction could kill. Autologous, on the other hand, is a safe proposition. The doctor has been in the profession since 1978 and has treated over 40 patients with acute degenerative disorders like, multiple sclerosis. To read the transcript of the video about autologous and adult stem cell transplant in Mexico, click the link above. Related Searches: Autologous stem cell transplant mexico, Hematopoietic stem cell transplantation mexico, Stem Cell Transplantation in Adults mexico, Stem cell treatment ms mexico, stem cell treatment glaucoma mexico, stem cell therapy brain disorders mexico, stem cell therapy brain injury mexico, stem cell treatment spinal cord MX,From:mexicohealthViews:2 0ratingsTime:03:08More inPeople Blogs

Continued here:
Autologous and Adult Stem Cells Transplant in Mexico - Video

Washington, November 6 (ANI): Administering to patients stem cells derived from their own bone marrow either three or seven days after a heart attack is safe but does not improve heart function six months later, according to a clinical trial.

The results of the trial, called Transplantation In Myocardial Infarction Evaluation (TIME), mirror a previous, related study, LateTIME, which found that such cells (called autologous stem cells) given two to three weeks after a heart attack did not improve heart function.

Both TIME and LateTIME were conducted by the Cardiovascular Cell Therapy Research Network (CCTRN), sponsored by the NIH's National Heart, Lung, and Blood Institute.

"This study was extremely valuable even though it did not provide a demonstrated health benefit after six months," said Sonia Skarlatos, Ph.D., deputy director of NHLBI's Division of Cardiovascular Sciences and member of the CCTRN.

"Heart stem cell therapy research is still in its infancy, and results from early trials have varied greatly due to differences in the numbers of stem cells injected, the delivery methods used, and the compositions of the study populations. With TIME and LateTIME, we have established both safety and baseline results in two large studies that followed the same procedures for growing and then administering stem cells. This standard will inform the next steps in research on the use of stem cells to repair damaged hearts," she stated.

Fellow CCTRN member Jay Travese, M.D., of the Minneapolis Heart Institute added, "With this baseline now set, we can start to adjust some of the components of the protocol to grow and administer stem cell to find cases where the procedure may improve function."

"For example, this therapy may work better in different population groups, or we might need to use new cell types or new methods of delivery," he noted.

Skarlatos said that another advantage of the TIME study is that CCTRN is storing samples of the stem cells taken from the participants. Investigators can examine the relationship between people who showed significant improvement during the study and the characteristics of their stem cells. Such a comparison may offer insights on the cell traits that are associated with clinical improvement.

The findings will be presented at the American Heart Association (AHA) 2012 Scientific Sessions in Los Angeles and will appear concurrently in the Journal of the American Medical Association. (ANI)

See the article here:
Stem cell therapy may not improve recovery after heart attack